Publication | Open Access

Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors

Pharmacodynamic StudyOncologyMedicineP-glycoprotein InhibitorPharmacotherapyRefractory Solid TumorsAnti-cancer AgentCancer TreatmentPharmacologyRadiation Oncology